Skip to main content
PMC home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1996 Jun;164(6):486–491.

Isoniazid-related fatal hepatitis.

P S Millard 1, T C Wilcosky 1, S J Reade-Christopher 1, D J Weber 1
PMCID: PMC1303623  PMID: 8764622

Abstract

To describe the clinical and demographic characteristics of fatal hepatitis due to single-drug isoniazid preventive therapy for tuberculosis, we did a survey of cases from state health departments, published case reports, and reports to the Centers for Disease Control and Prevention from 1970 to 1992. Of 108 reported cases, some clinical information was available for 76. A medical review panel judged 39 of these deaths as probably due to isoniazid hepatitis and 23 deaths as possibly due to isoniazid hepatitis. Of the 62 probable and possible cases combined, 50 (81%) were female, 49 (79%) were non-Hispanic black or Hispanic, and 19 (31%) were younger than 35 years. The median duration of isoniazid preventive therapy before symptom onset was 16 weeks. Of the 60 cases with symptom information, 54 (90%) presented with jaundice. Of the 62 cases, 26 (42%) were monitored monthly in accordance with current recommendations, and 6 of the patients were younger than 35 years. We estimate that the rate of fatal isoniazid hepatitis among patients in the public sector was no greater than 4.2 per 100,000 persons beginning therapy and no greater than 7 per 100,000 persons completing therapy. Adherence to isoniazid preventive therapy guidelines apparently reduces, but does not eliminate, the risk of fatal hepatitis. Careful patient selection, education, and monitoring are critical for minimizing that risk.

Full text

PDF
486

Images in this article

488Figure 1.
on p.488
488Figure 2.
on p.488

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Black M., Mitchell J. R., Zimmerman H. J., Ishak K. G., Epler G. R. Isoniazid-associated hepatitis in 114 patients. Gastroenterology. 1975 Aug;69(2):289–302. [PubMed] [Google Scholar]
  2. Comstock G. W., Ferebee S. H., Hammes L. M. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis. 1967 Jun;95(6):935–943. doi: 10.1164/arrd.1967.95.6.935. [DOI] [PubMed] [Google Scholar]
  3. Comstock G. W. Prevention of tuberculosis among tuberculin reactors: maximizing benefits, minimizing risks. JAMA. 1986 Nov 21;256(19):2729–2730. [PubMed] [Google Scholar]
  4. FEREBEE S. H., MOUNT F. W., MURRAY F. J., LIVESAY V. T. A CONTROLLED TRIAL OF ISONIAZID PROPHYLAXIS IN MENTAL INSTITUTIONS. Am Rev Respir Dis. 1963 Aug;88:161–175. doi: 10.1164/arrd.1963.88.2.161. [DOI] [PubMed] [Google Scholar]
  5. FEREBEE S. H., MOUNT F. W. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis. 1962 Apr;85:490–510. doi: 10.1164/arrd.1962.85.4.490. [DOI] [PubMed] [Google Scholar]
  6. Franks A. L., Binkin N. J., Snider D. E., Jr, Rokaw W. M., Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep. 1989 Mar-Apr;104(2):151–155. [PMC free article] [PubMed] [Google Scholar]
  7. Gal A. A., Klatt E. C. Fatal isoniazid hepatitis in a child. Pediatr Infect Dis. 1986 Jul-Aug;5(4):490–491. doi: 10.1097/00006454-198607000-00027. [DOI] [PubMed] [Google Scholar]
  8. Garibaldi R. A., Drusin R. E., Ferebee S. H., Gregg M. B. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis. 1972 Sep;106(3):357–365. doi: 10.1164/arrd.1972.106.3.357. [DOI] [PubMed] [Google Scholar]
  9. Iseman M. D., Miller B. If a tree falls in the middle of the forest. Isoniazid and hepatitis. Am Rev Respir Dis. 1989 Sep;140(3):575–576. doi: 10.1164/ajrccm/140.3.575. [DOI] [PubMed] [Google Scholar]
  10. Israel H. L., Gottlieb J. E., Maddrey W. C. Perspective: preventive isoniazid therapy and the liver. Chest. 1992 May;101(5):1298–1301. doi: 10.1378/chest.101.5.1298. [DOI] [PubMed] [Google Scholar]
  11. Kopanoff D. E., Snider D. E., Jr, Caras G. J. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1978 Jun;117(6):991–1001. doi: 10.1164/arrd.1978.117.6.991. [DOI] [PubMed] [Google Scholar]
  12. Levin M. L., Moodie A. S. Isoniazid prophylaxis and deaths in Baltimore, 1972. Md State Med J. 1974 Nov;23(11):64–67. [PubMed] [Google Scholar]
  13. MERRITT A. D., FETTER B. F. Toxic hepatic necrosis (hepatitis) due to isoniazid: report of a case with cirrhosis and death due to hemorrhage from esophageal varices. Ann Intern Med. 1959 Mar;50(3):804–810. doi: 10.7326/0003-4819-50-3-804. [DOI] [PubMed] [Google Scholar]
  14. Maddrey W. C., Boitnott J. K. Isoniazid hepatitis. Ann Intern Med. 1973 Jul;79(1):1–12. doi: 10.7326/0003-4819-79-1-1. [DOI] [PubMed] [Google Scholar]
  15. Moulding T. S., Redeker A. G., Kanel G. C. Acetaminophen, isoniazid, and hepatic toxicity. Ann Intern Med. 1991 Mar 1;114(5):431–431. doi: 10.7326/0003-4819-114-5-431_2. [DOI] [PubMed] [Google Scholar]
  16. Moulding T. S., Redeker A. G., Kanel G. C. Twenty isoniazid-associated deaths in one state. Am Rev Respir Dis. 1989 Sep;140(3):700–705. doi: 10.1164/ajrccm/140.3.700. [DOI] [PubMed] [Google Scholar]
  17. Rose D. N., Schechter C. B., Silver A. L. The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactors. JAMA. 1986 Nov 21;256(19):2709–2713. [PubMed] [Google Scholar]
  18. Salpeter S. R. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med. 1993 Nov;159(5):560–564. [PMC free article] [PubMed] [Google Scholar]
  19. Selwyn P. A., Sckell B. M., Alcabes P., Friedland G. H., Klein R. S., Schoenbaum E. E. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA. 1992 Jul 22;268(4):504–509. [PubMed] [Google Scholar]
  20. Snider D. E., Jr, Caras G. J. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis. 1992 Feb;145(2 Pt 1):494–497. doi: 10.1164/ajrccm/145.2_Pt_1.494. [DOI] [PubMed] [Google Scholar]
  21. Tsevat J., Taylor W. C., Wong J. B., Pauker S. G. Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis. 1988 Jan;137(1):215–220. doi: 10.1164/ajrccm/137.1.215. [DOI] [PubMed] [Google Scholar]
  22. Vanderhoof J. A., Ament M. E. Fatal hepatic necrosis due to isoniazid chemoprophylaxis in a 15-year-old girl. J Pediatr. 1976 May;88(5):867–868. doi: 10.1016/s0022-3476(76)81134-1. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES